Parkinson's Disease最新文献_第2页

Hypoperfusion in Supramarginal and Orbital Gyrus, Position Discrimination Test, and Microsaccades as a Predictor of Pisa Syndrome in Parkinson’s Disease 帕金森病患者皮萨综合征的帕金森上边缘回和眶回、位置辨别测试和微注视的低灌注预示因素

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-05-30 DOI: 10.1155/2024/5550362

Asako Yoritaka, Tetsuo Hayashi, Keiko Fusegi, Sachiko Nakayama, Jun Haneda, Nobutaka Hattori

Patients with Parkinson’s disease (PD) experience significantly reduced quality of life when PD is complicated with Pisa syndrome (PS). PS is a postural abnormality associated with a lateral bending of the trunk, causing the patient to lean to one side. Microsaccades during fixation are transmitted to the visual cortex, and this gaze movement may be impaired in PD. We aimed to detect presymptomatic signs of PS. We enrolled 50 patients with PD without dementia and investigated the visual systems in patients with concurrent PD and PS based on a Romberg ratio of<1.0. Gaze analysis, pupil diameter, stabilization tests, neuropsychological tests, and cerebral perfusion scintigraphy were reviewed and statistically analyzed. Two years later, we divided the patients into three groups as follows: PISA++ (patients who had PS at enrollment), PISA-+ (patients without PS that developed PS during the 2-year period), and PISA-- (patients without PS that did not develop PS during the 2-year period). The PISA-+ group exhibited a significantly higher daily levodopa dose and longer fixations, as well as lower position discrimination, Wechsler Adult Intelligence Scale-Third Edition blocking, and blood flow in the left supramarginal and orbital gyri than that in the PISA-- group. The PISA++ group showed a significantly longer fixation time and lower Mini-Mental State Examination score, Romberg ratio of area, amplitude, velocity of microsaccades, and blood flow in the left precuneus and cuneus than that in the PISA-+ group. Before the onset of PS, hypoperfusion occurred in the correlative visual cortex and the position discrimination test. Patients with PS have reduced saccades and slow microsaccades.

帕金森病（Parkinson's disease，PD）患者如果并发比萨综合征（Pisa syndrome，PS），生活质量就会明显下降。皮萨综合征是一种姿势异常，与躯干侧弯有关，导致患者身体向一侧倾斜。固定时的微注视会传递到视觉皮层，而这种注视运动在帕金森氏症患者中可能会受损。我们的目的是检测 PS 的症状前体征。我们招募了 50 名没有痴呆症的帕金森病患者，并根据朗伯格比率为 1.0 的标准调查了同时患有帕金森病和 PS 的患者的视觉系统。我们对凝视分析、瞳孔直径、稳定性测试、神经心理学测试和脑灌注闪烁成像进行了回顾性研究和统计分析。两年后，我们将患者分为以下三组：PISA++组（入院时患有 PS 的患者）、PISA-+组（无 PS 但在两年内出现 PS 的患者）和 PISA-- 组（无 PS 但在两年内未出现 PS 的患者）。与PISA--组相比，PISA-+组的左旋多巴日剂量明显增加，固定时间明显延长，位置辨别力、韦氏成人智力量表--第三版阻滞以及左侧边际上和眼眶回的血流量均低于PISA--组。与 PISA-+ 组相比，PISA++ 组的固定时间明显较长，迷你精神状态检查得分、微注视的面积、振幅和速度的罗姆伯格比率以及左侧楔前叶和楔叶的血流量均较低。在 PS 发病前，相关视觉皮层和位置辨别测试出现低灌注。PS患者的眼球回转和微回转速度减慢。

{"title":"Hypoperfusion in Supramarginal and Orbital Gyrus, Position Discrimination Test, and Microsaccades as a Predictor of Pisa Syndrome in Parkinson’s Disease","authors":"Asako Yoritaka, Tetsuo Hayashi, Keiko Fusegi, Sachiko Nakayama, Jun Haneda, Nobutaka Hattori","doi":"10.1155/2024/5550362","DOIUrl":"https://doi.org/10.1155/2024/5550362","url":null,"abstract":"Patients with Parkinson’s disease (PD) experience significantly reduced quality of life when PD is complicated with Pisa syndrome (PS). PS is a postural abnormality associated with a lateral bending of the trunk, causing the patient to lean to one side. Microsaccades during fixation are transmitted to the visual cortex, and this gaze movement may be impaired in PD. We aimed to detect presymptomatic signs of PS. We enrolled 50 patients with PD without dementia and investigated the visual systems in patients with concurrent PD and PS based on a Romberg ratio of<1.0. Gaze analysis, pupil diameter, stabilization tests, neuropsychological tests, and cerebral perfusion scintigraphy were reviewed and statistically analyzed. Two years later, we divided the patients into three groups as follows: PISA++ (patients who had PS at enrollment), PISA-+ (patients without PS that developed PS during the 2-year period), and PISA-- (patients without PS that did not develop PS during the 2-year period). The PISA-+ group exhibited a significantly higher daily levodopa dose and longer fixations, as well as lower position discrimination, Wechsler Adult Intelligence Scale-Third Edition blocking, and blood flow in the left supramarginal and orbital gyri than that in the PISA-- group. The PISA++ group showed a significantly longer fixation time and lower Mini-Mental State Examination score, Romberg ratio of area, amplitude, velocity of microsaccades, and blood flow in the left precuneus and cuneus than that in the PISA-+ group. Before the onset of PS, hypoperfusion occurred in the correlative visual cortex and the position discrimination test. Patients with PS have reduced saccades and slow microsaccades.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"5 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141198101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Mixed Methods Approach to Explore the Experience of Pain and Its Management in People with Parkinson’s Disease 探索帕金森病患者疼痛体验及其管理的混合方法

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-05-25 DOI: 10.1155/2024/8515400

Vanessa Nguy, Bernadette Brady, Leanne M. Hassett, Colleen G. Canning, James M. Elliott, Natalie E. Allen

Introduction. Pain in Parkinson’s disease (PD) is common but poorly understood, with most research to date taking a mechanistic approach. This mixed methods study takes a broader biopsychosocial approach to assess and describe contributors of pain and explore pain management and the relationship between pain and physical activity in people with PD (PwPD) and chronic pain. Methods. A structured survey evaluated respondents’ contributors of pain using standardized, self-report assessments of the following: pain, peripheral neuropathy, central nociplastic change, emotional dysregulation or pathology, and maladaptive cognitions. Semistructured individual interviews were conducted with purposively sampled survey participants and analyzed using inductive thematic analysis. Results. Eighty-nine PwPD (mean age 67 years, 55% female) completed the survey. The most common pain contributors were maladaptive cognitions (62%), central nociplastic change (49%), and emotional dysregulation (44%). Approaches to pain management and the response to physical activity were variable within and across individuals with different pain contributors. Four themes emerged from interviews with 24 participants: (1) causative perceptions of pain are diverse; (2) sense of control influences disease acceptance and exercise self-efficacy; (3) belief in the value of therapy; and (4) pain as the unspoken PD symptom. Physical activity was used by PwPD for pain management; however, the relationship between pain and physical activity varied based on sense of control. Conclusions. Clinicians should screen for pain and assess its contributors to provide individualized, multidimensional pain management that considers the biological, psychological, and social factors of pain in PwPD. It is plausible that such an approach would promote a better sense of control for PwPD.

简介。帕金森病（Parkinson's disease，PD）中的疼痛很常见，但人们对其了解甚少，迄今为止的大多数研究都采用了机理研究方法。这项混合方法研究采用更广泛的生物-心理-社会方法来评估和描述疼痛的诱因，并探讨帕金森病患者（PwPD）和慢性疼痛患者的疼痛管理以及疼痛与体力活动之间的关系。调查方法采用标准化的自我报告评估方法对受访者的疼痛诱因进行结构化调查，评估内容包括：疼痛、周围神经病变、中枢神经病变、情绪失调或病理以及适应不良认知。对有目的抽样调查的参与者进行了半结构化个人访谈，并采用归纳式主题分析法进行了分析。结果89 名残疾人（平均年龄 67 岁，55% 为女性）完成了调查。最常见的疼痛诱因是适应不良认知（62%）、中枢神经畸形改变（49%）和情绪失调（44%）。在不同疼痛诱因的个体内部和个体之间，疼痛管理方法和对体育锻炼的反应各不相同。在对 24 名参与者的访谈中，我们发现了四个主题：（1）对疼痛的因果关系有不同的认识；（2）控制感影响对疾病的接受程度和运动自我效能；（3）对治疗价值的信念；以及（4）疼痛是无法言说的帕金森病症状。残疾人通过体育锻炼来控制疼痛；然而，疼痛与体育锻炼之间的关系因控制感而异。结论。临床医生应筛查疼痛并评估其诱因，以提供个性化、多维度的疼痛管理，同时考虑到导致 PwPD 患者疼痛的生物、心理和社会因素。这种方法有可能提高残疾人的控制感。

{"title":"A Mixed Methods Approach to Explore the Experience of Pain and Its Management in People with Parkinson’s Disease","authors":"Vanessa Nguy, Bernadette Brady, Leanne M. Hassett, Colleen G. Canning, James M. Elliott, Natalie E. Allen","doi":"10.1155/2024/8515400","DOIUrl":"https://doi.org/10.1155/2024/8515400","url":null,"abstract":"Introduction. Pain in Parkinson’s disease (PD) is common but poorly understood, with most research to date taking a mechanistic approach. This mixed methods study takes a broader biopsychosocial approach to assess and describe contributors of pain and explore pain management and the relationship between pain and physical activity in people with PD (PwPD) and chronic pain. Methods. A structured survey evaluated respondents’ contributors of pain using standardized, self-report assessments of the following: pain, peripheral neuropathy, central nociplastic change, emotional dysregulation or pathology, and maladaptive cognitions. Semistructured individual interviews were conducted with purposively sampled survey participants and analyzed using inductive thematic analysis. Results. Eighty-nine PwPD (mean age 67 years, 55% female) completed the survey. The most common pain contributors were maladaptive cognitions (62%), central nociplastic change (49%), and emotional dysregulation (44%). Approaches to pain management and the response to physical activity were variable within and across individuals with different pain contributors. Four themes emerged from interviews with 24 participants: (1) causative perceptions of pain are diverse; (2) sense of control influences disease acceptance and exercise self-efficacy; (3) belief in the value of therapy; and (4) pain as the unspoken PD symptom. Physical activity was used by PwPD for pain management; however, the relationship between pain and physical activity varied based on sense of control. Conclusions. Clinicians should screen for pain and assess its contributors to provide individualized, multidimensional pain management that considers the biological, psychological, and social factors of pain in PwPD. It is plausible that such an approach would promote a better sense of control for PwPD.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"22 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141146170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trait Impulsivity as a Feature of Parkinson’s Disease Treatment and Progression 特质冲动是帕金森病治疗和进展的一个特征

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-05-11 DOI: 10.1155/2024/8770997

Holly Spencer, Ryan S. Anderton

Heightened trait impulsivity in both subclinical and pathological senses is becoming increasingly recognised in Parkinson’s disease (PD). Impulsive behaviours and impulse control disorders (ICDs) are a consequence of perturbation to the rewards pathway leading individuals to conduct activities in a repetitive, excessive, and maladaptive fashion. Commonly linked to PD, heightened trait impulsivity has been found to primarily manifest in the forms of hypersexuality, pathological gambling, compulsive shopping, and binge eating, all of which may significantly impact social and financial standing. Subsequent burden to quality of life for both individuals with PD and caregivers are common. Although risk factors and indicators for ICDs in PD are currently lacking, it is recognised that the condition is often precipitated by dopamine replacement therapies, primarily dopamine agonist administration. While this nonmotor symptom is being increasingly diagnosed in PD populations, it remains relatively elusive in comparison to its motor counterparts. Through discussion of impulsivity characteristics, neuroanatomy, and neurochemistry, in addition to reviewing existing research on the potential contributing factors to impulsivity in PD, this review highlights impulsivity as a significant and detrimental PD symptom. Thus, emphasising the imperative need to establish efficacious diagnostic tools and treatments.

在帕金森病（PD）中，亚临床和病理意义上的特质冲动性越来越被人们所认识。冲动行为和冲动控制障碍（ICD）是奖赏通路受到干扰的结果，导致患者以重复、过度和不适应的方式进行活动。与帕金森病有关的常见特质冲动行为主要表现为性欲亢进、病态赌博、强迫购物和暴饮暴食，所有这些行为都会严重影响社交和经济状况。对帕金森病患者和照护者的生活质量造成的后续负担也很常见。尽管目前尚缺乏帕金森病 ICD 的风险因素和指标，但人们认识到，多巴胺替代疗法（主要是多巴胺激动剂的使用）通常会诱发这种症状。虽然这种非运动症状在帕金森病患者中的诊断率越来越高，但与运动症状相比，它仍然相对难以捉摸。通过对冲动性特征、神经解剖学和神经化学的讨论，以及对导致帕金森病冲动性的潜在因素的现有研究的回顾，本综述强调冲动性是一种重要的、有害的帕金森病症状。因此，本综述强调建立有效的诊断工具和治疗方法势在必行。

{"title":"Trait Impulsivity as a Feature of Parkinson’s Disease Treatment and Progression","authors":"Holly Spencer, Ryan S. Anderton","doi":"10.1155/2024/8770997","DOIUrl":"https://doi.org/10.1155/2024/8770997","url":null,"abstract":"Heightened trait impulsivity in both subclinical and pathological senses is becoming increasingly recognised in Parkinson’s disease (PD). Impulsive behaviours and impulse control disorders (ICDs) are a consequence of perturbation to the rewards pathway leading individuals to conduct activities in a repetitive, excessive, and maladaptive fashion. Commonly linked to PD, heightened trait impulsivity has been found to primarily manifest in the forms of hypersexuality, pathological gambling, compulsive shopping, and binge eating, all of which may significantly impact social and financial standing. Subsequent burden to quality of life for both individuals with PD and caregivers are common. Although risk factors and indicators for ICDs in PD are currently lacking, it is recognised that the condition is often precipitated by dopamine replacement therapies, primarily dopamine agonist administration. While this nonmotor symptom is being increasingly diagnosed in PD populations, it remains relatively elusive in comparison to its motor counterparts. Through discussion of impulsivity characteristics, neuroanatomy, and neurochemistry, in addition to reviewing existing research on the potential contributing factors to impulsivity in PD, this review highlights impulsivity as a significant and detrimental PD symptom. Thus, emphasising the imperative need to establish efficacious diagnostic tools and treatments.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"155 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140929612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Priority Goals and Underlying Impairments Contributing to Goal-Related Problems of People with Parkinson’s Disease Receiving a Community-Based Rehabilitation Program 接受社区康复计划的帕金森病患者的优先目标和导致目标相关问题的潜在障碍

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-04-12 DOI: 10.1155/2024/9465326

Sarah J. Davies, Hannah L. Gullo, Emmah Doig

Background. Goal setting is a core rehabilitation practice in Parkinson’s disease (PD). Targeting therapy towards specific goals leads to greater improvements in performance and psychosocial outcomes. Goal setting in PD is feasible, and although the nature of goals has been described in previous studies, the underlying impairments related to goals have not been described. Understanding the nature of goals ensures that interventions for people with PD are aligned with their needs and priorities. Understanding the underlying impairments highlights which symptoms have the biggest impact on daily life and is necessary for planning appropriate interventions to target them. Aim. To describe the nature of the goals of people with PD; the underlying impairments related to goals; and to compare differences between high and low priority goals. Method. Deductive content analysis was used to map goal statements to the international classification of function (ICF) activity and participation category and to map therapist field notes detailing the primary underlying impairment to the ICF Body Functions category. These results were then compared across goal priority rankings. Results. 88 goals of 22 people with PD were analysed. We found that people with PD set diverse goals across all chapters of the ICF Activity and Participation category, with “self-care” goals making up the highest proportion of goals. The primary underlying impairment related to the goals was predominantly related to impairments in “mental functions” under the Body Functions category. Regardless of goal priority, most goal-related underlying impairments were found to be in the “mental functions” category. Conclusion. The goals of this sample of community-dwelling people with PD highlight their diverse needs and priorities. These findings indicate that nonmotor symptoms, namely, executive dysfunction and amotivation most commonly impact the performance of and participation in activities of greatest importance to people with PD. This trial is registered with ACTRN12621001483842.

背景。目标设定是帕金森病（PD）的核心康复实践。针对特定目标进行治疗可大大改善患者的表现和心理社会效果。帕金森病的目标设定是可行的，尽管之前的研究已经描述了目标的性质，但与目标相关的潜在障碍尚未得到描述。了解目标的性质可确保对帕金森氏症患者的干预符合他们的需求和优先事项。了解潜在障碍可突出哪些症状对日常生活的影响最大，这对于规划针对这些症状的适当干预措施非常必要。目的描述帕金森病患者目标的性质；与目标相关的潜在障碍；比较高优先级目标和低优先级目标之间的差异。方法。使用演绎内容分析法将目标陈述与国际功能分类（ICF）的活动和参与类别进行映射，并将治疗师的现场记录与国际功能分类的身体功能类别进行映射，详细说明主要的潜在障碍。然后将这些结果与目标优先级进行比较。结果。对 22 名帕金森氏症患者的 88 个目标进行了分析。我们发现，帕金森氏症患者在《国际功能、残疾和健康分类》的 "活动和参与 "类别的所有章节中设定了不同的目标，其中 "自我护理 "目标所占比例最高。与目标相关的主要基本损伤主要与身体功能类别下的 "精神功能 "损伤有关。无论目标的优先级如何，大多数与目标相关的潜在损伤都属于 "心理功能 "类别。结论这些居住在社区的帕金森病患者的目标突出了他们的不同需求和优先事项。这些研究结果表明，非运动症状，即执行功能障碍和缺乏动力，最常影响帕金森病患者从事和参与最重要的活动。该试验的注册号为 ACTRN12621001483842。

{"title":"The Priority Goals and Underlying Impairments Contributing to Goal-Related Problems of People with Parkinson’s Disease Receiving a Community-Based Rehabilitation Program","authors":"Sarah J. Davies, Hannah L. Gullo, Emmah Doig","doi":"10.1155/2024/9465326","DOIUrl":"https://doi.org/10.1155/2024/9465326","url":null,"abstract":"Background. Goal setting is a core rehabilitation practice in Parkinson’s disease (PD). Targeting therapy towards specific goals leads to greater improvements in performance and psychosocial outcomes. Goal setting in PD is feasible, and although the nature of goals has been described in previous studies, the underlying impairments related to goals have not been described. Understanding the nature of goals ensures that interventions for people with PD are aligned with their needs and priorities. Understanding the underlying impairments highlights which symptoms have the biggest impact on daily life and is necessary for planning appropriate interventions to target them. Aim. To describe the nature of the goals of people with PD; the underlying impairments related to goals; and to compare differences between high and low priority goals. Method. Deductive content analysis was used to map goal statements to the international classification of function (ICF) activity and participation category and to map therapist field notes detailing the primary underlying impairment to the ICF Body Functions category. These results were then compared across goal priority rankings. Results. 88 goals of 22 people with PD were analysed. We found that people with PD set diverse goals across all chapters of the ICF Activity and Participation category, with “self-care” goals making up the highest proportion of goals. The primary underlying impairment related to the goals was predominantly related to impairments in “mental functions” under the Body Functions category. Regardless of goal priority, most goal-related underlying impairments were found to be in the “mental functions” category. Conclusion. The goals of this sample of community-dwelling people with PD highlight their diverse needs and priorities. These findings indicate that nonmotor symptoms, namely, executive dysfunction and amotivation most commonly impact the performance of and participation in activities of greatest importance to people with PD. This trial is registered with ACTRN12621001483842.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"35 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140574180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Home-Based Titration with Duodenal Infusion of Levodopa-Carbidopa Intestinal Gel in People with Parkinson’s Disease: An Observational Feasibility Study 帕金森病患者在家中通过十二指肠输注左旋多巴-卡比多巴肠凝胶进行滴定：观察性可行性研究

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-04-08 DOI: 10.1155/2024/5522824

Trine Hørmann Thomsen, Nick Schou Nielsen, Asher Lou Isenberg, Michael Hougaard Møller, Jesper Bøje Clausen, Inge Mona Schack Frederiksen, Louise Olsen, Mahsa Javidi, Jeanet Vilhelmsen, Marc Klee Olsen, Bo Biering-Sørensen

Background. Testing and titration of the right levodopa equivalent dose are usually performed during a hospital admission. However, optimal dose titration in people with Parkinson’s disease (PwPs) may depend on home environment, emotional stress, and physical activity of everyday life. Objective. Firstly, to evaluate the feasibility and safety of a home-based LCIG titration program and patients’/caregivers’ satisfaction. Secondly, to identify barriers and facilitators for home-based titration. Method. This study assesses the feasibility and safety of home-based titration of levodopa duodenal infusions with the use of self-reported evaluation questionnaires with open-ended questions included, registration of total time used, and number of contacts/visits. A telemedicine solution was used to remotely monitor the patients, adjust treatment, and provide support and guidance to patients and caregivers. Results. Ten of 12 PwPs (5 females and 7 males) completed the total titration program. Eight of the 12 PwPs were dependent on help. These 8 PwPs also had a high burden of nonmotor symptoms (NMS). Cognitive impairments varied in severity (range 16–30). Time spent with home visits was on average 93.4 minutes (ranging from 35 to 180 minutes), and the length of the total titration (LCIG initiation to termination of titration) was on average 3.4 days with 2–5 (mean 3.2) contacts/visits with PD team members. The average score on the satisfaction evaluation questionnaires was lower in the caregiver group (mean 31.8) than the PwP outcome (mean 36.2). Conclusions. Telehealth-assisted home-based titration programs are feasible due to the length of the titration period, number of contacts, and time spent in PwPs’ private homes, are rated satisfactory and safe by PwPs and caregivers, and may be a substitute for in-hospital treatment. Clinical recommendations including facilitators and barriers from a patient/caregiver perspective are displayed. This trial is registered with NCT4196647.

背景。测试和滴定合适的左旋多巴等效剂量通常在入院时进行。然而，帕金森病患者的最佳剂量滴定可能取决于家庭环境、情绪压力和日常生活中的体力活动。研究目的首先，评估基于家庭的 LCIG 滴定计划的可行性和安全性，以及患者/护理人员的满意度。其次，确定居家滴定的障碍和促进因素。方法。本研究通过使用自我报告评估问卷（包括开放式问题）、登记所用总时间和联系/访问次数，评估左旋多巴十二指肠输液居家滴注的可行性和安全性。远程医疗解决方案用于远程监控患者、调整治疗方案以及为患者和护理人员提供支持和指导。结果。12 名患者中有 10 名（5 名女性和 7 名男性）完成了整个滴定计划。在这 12 名患者中，有 8 名需要依赖他人的帮助。这 8 名患者的非运动症状（NMS）负担也很重。认知障碍的严重程度各不相同（范围在 16-30 之间）。家访时间平均为 93.4 分钟（从 35 分钟到 180 分钟不等），整个滴定过程（从开始使用 LCIG 到终止滴定）平均为 3.4 天，与 PD 小组成员接触/家访 2-5 次（平均 3.2 次）。护理人员组满意度评估问卷的平均得分（平均 31.8 分）低于患者组（平均 36.2 分）。结论远程医疗辅助家庭滴定项目是可行的，因为滴定时间长、接触次数多、在患者私人家中花费的时间少，患者和护理人员对其满意度和安全性的评价也很高，可以替代院内治疗。临床建议包括从患者/护理者角度出发的促进因素和障碍。该试验已在 NCT4196647 上注册。

{"title":"Home-Based Titration with Duodenal Infusion of Levodopa-Carbidopa Intestinal Gel in People with Parkinson’s Disease: An Observational Feasibility Study","authors":"Trine Hørmann Thomsen, Nick Schou Nielsen, Asher Lou Isenberg, Michael Hougaard Møller, Jesper Bøje Clausen, Inge Mona Schack Frederiksen, Louise Olsen, Mahsa Javidi, Jeanet Vilhelmsen, Marc Klee Olsen, Bo Biering-Sørensen","doi":"10.1155/2024/5522824","DOIUrl":"https://doi.org/10.1155/2024/5522824","url":null,"abstract":"Background. Testing and titration of the right levodopa equivalent dose are usually performed during a hospital admission. However, optimal dose titration in people with Parkinson’s disease (PwPs) may depend on home environment, emotional stress, and physical activity of everyday life. Objective. Firstly, to evaluate the feasibility and safety of a home-based LCIG titration program and patients’/caregivers’ satisfaction. Secondly, to identify barriers and facilitators for home-based titration. Method. This study assesses the feasibility and safety of home-based titration of levodopa duodenal infusions with the use of self-reported evaluation questionnaires with open-ended questions included, registration of total time used, and number of contacts/visits. A telemedicine solution was used to remotely monitor the patients, adjust treatment, and provide support and guidance to patients and caregivers. Results. Ten of 12 PwPs (5 females and 7 males) completed the total titration program. Eight of the 12 PwPs were dependent on help. These 8 PwPs also had a high burden of nonmotor symptoms (NMS). Cognitive impairments varied in severity (range 16–30). Time spent with home visits was on average 93.4 minutes (ranging from 35 to 180 minutes), and the length of the total titration (LCIG initiation to termination of titration) was on average 3.4 days with 2–5 (mean 3.2) contacts/visits with PD team members. The average score on the satisfaction evaluation questionnaires was lower in the caregiver group (mean 31.8) than the PwP outcome (mean 36.2). Conclusions. Telehealth-assisted home-based titration programs are feasible due to the length of the titration period, number of contacts, and time spent in PwPs’ private homes, are rated satisfactory and safe by PwPs and caregivers, and may be a substitute for in-hospital treatment. Clinical recommendations including facilitators and barriers from a patient/caregiver perspective are displayed. This trial is registered with NCT4196647.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"38 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140574402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkisnsonism 聚焦超声丘脑切开术缓解非典型帕金森氏症患者的震颤

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-03-05 DOI: 10.1155/2024/6643510

Alon Sinai, Maria Nassar, Lev Shornikov, Marius Constantinescu, Menashe Zaaroor, Ilana Schlesinger

Background. Magnetic resonance imaging (MRI)-guided focused ultrasound (FUS) VIM-thalamotomy has established efficacy and safety in tremor relief in patients with essential tremor and Parkinson’s disease. The efficacy and safety in patients with atypical parkinsonism have not been reported. Objective. To report on the efficacy and safety of FUS VIM-thalamotomy in 8 patients with parkinsonism, multiple system atrophy-Parkinsonian type (MSA-P) (n = 5), and dementia with Lewy bodies (DLB) (n = 3). Methods. Tremor was assessed in the treated hemibody using the Clinical Rating Scale for Tremor (CRST). The motor Unified MSA Rating Scale (UMSAR) was used in the MSA-P and motor sections of the Unified Parkinson’s Disease Rating Scale (UPDRS-III) in DLB patients. Cognition was measured using the Montreal Cognitive Assessment (MoCA). Results. In MSA-P and DLB patients, there was immediate tremor relief. CRST scores measured on the treated side improved compared to baseline. During the follow-up of up to 1 year tremor reduction persisted. The change in CRST scores at different time points did not reach statistical significance, probably due to the small sample size. Adverse events were transient and resolved within a year. Conclusions. In our experience, FUS VIM-thalamotomy was effective in patients with MSA-P and DLB. Larger, controlled studies are needed to verify our preliminary observations.

背景。磁共振成像（MRI）引导下的聚焦超声（FUS）VIM-丘脑切开术对缓解本质性震颤和帕金森病患者的震颤具有疗效和安全性。但对非典型帕金森病患者的疗效和安全性尚未见报道。目的报告 FUS VIM-胼胝体切开术在 8 例帕金森病、多系统萎缩-帕金森病型（MSA-P）（n = 5）和路易体痴呆（DLB）（n = 3）患者中的疗效和安全性。研究方法使用震颤临床评分量表（CRST）评估治疗半身的震颤情况。在DLB患者的MSA-P和统一帕金森病评定量表（UPDRS-III）的运动部分使用运动统一MSA评定量表（UMSAR）。认知能力采用蒙特利尔认知评估（MoCA）进行测量。结果MSA-P和DLB患者的震颤症状立即得到缓解。与基线相比，治疗侧的 CRST 评分有所提高。在长达 1 年的随访期间，震颤的缓解仍在持续。可能由于样本量较小，不同时间点的 CRST 评分变化未达到统计学意义。不良反应均为一过性，并在一年内缓解。结论根据我们的经验，FUS VIM-丘脑切开术对 MSA-P 和 DLB 患者有效。我们需要更大规模的对照研究来验证我们的初步观察结果。

{"title":"Focused Ultrasound Thalamotomy for Tremor Relief in Atypical Parkisnsonism","authors":"Alon Sinai, Maria Nassar, Lev Shornikov, Marius Constantinescu, Menashe Zaaroor, Ilana Schlesinger","doi":"10.1155/2024/6643510","DOIUrl":"https://doi.org/10.1155/2024/6643510","url":null,"abstract":"Background. Magnetic resonance imaging (MRI)-guided focused ultrasound (FUS) VIM-thalamotomy has established efficacy and safety in tremor relief in patients with essential tremor and Parkinson’s disease. The efficacy and safety in patients with atypical parkinsonism have not been reported. Objective. To report on the efficacy and safety of FUS VIM-thalamotomy in 8 patients with parkinsonism, multiple system atrophy-Parkinsonian type (MSA-P) (n = 5), and dementia with Lewy bodies (DLB) (n = 3). Methods. Tremor was assessed in the treated hemibody using the Clinical Rating Scale for Tremor (CRST). The motor Unified MSA Rating Scale (UMSAR) was used in the MSA-P and motor sections of the Unified Parkinson’s Disease Rating Scale (UPDRS-III) in DLB patients. Cognition was measured using the Montreal Cognitive Assessment (MoCA). Results. In MSA-P and DLB patients, there was immediate tremor relief. CRST scores measured on the treated side improved compared to baseline. During the follow-up of up to 1 year tremor reduction persisted. The change in CRST scores at different time points did not reach statistical significance, probably due to the small sample size. Adverse events were transient and resolved within a year. Conclusions. In our experience, FUS VIM-thalamotomy was effective in patients with MSA-P and DLB. Larger, controlled studies are needed to verify our preliminary observations.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"536 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140035731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson’s Disease 转染存活的多巴胺神经元中的 BDNF 基因并持续服用普拉克索可恢复双侧帕金森病大鼠模型的正常运动行为

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-02-21 DOI: 10.1155/2024/3885451

Alina Benítez-Castañeda, Verónica Anaya-Martínez, Armando de Jesús Espadas-Alvarez, Ana Luisa Gutierrez-Váldez, Luis Fernando Razgado-Hernández, Patricia Emmanuelle Reyna-Velazquez, Liz Quintero-Macias, Daniel Martínez-Fong, Benjamín Florán-Garduño, Jorge Aceves

In Parkinson’s disease (PD), progressive degeneration of nigrostriatal innervation leads to atrophy and loss of dendritic spines of striatal medium spiny neurons (MSNs). The loss disrupts corticostriatal transmission, impairs motor behavior, and produces nonmotor symptoms. Nigral neurons express brain-derived neurotropic factor (BDNF) and dopamine D3 receptors, both protecting the dopamine neurons and the spines of MSNs. To restore motor and nonmotor symptoms to normality, we assessed a combined therapy in a bilateral rat Parkinson’s model, with only 30% of surviving neurons. The preferential D3 agonist pramipexole (PPX) was infused for four ½ months via mini-osmotic pumps and one month after PPX initiation; the BDNF-gene was transfected into the surviving nigral cells using the nonviral transfection NTS-polyplex vector. Overexpression of the BDNF-gene associated with continuous PPX infusion restored motor coordination, balance, normal gait, and working memory. Recovery was also related to the restoration of the average number of dendritic spines of the striatal projection neurons and the number of TH-positive neurons of the substantia nigra and ventral tegmental area. These positive results could pave the way for further clinical research into this promising therapy.

在帕金森病（PD）中，黑质纹状体神经支配的逐渐退化会导致纹状体中刺神经元（MSN）树突棘的萎缩和缺失。这种损失会破坏皮质神经元的传导，损害运动行为，并产生非运动症状。黑质神经元表达脑源性神经营养因子（BDNF）和多巴胺 D3 受体，两者都能保护多巴胺神经元和 MSN 的棘。为了使运动症状和非运动症状恢复正常，我们在双侧大鼠帕金森病模型中评估了一种联合疗法。通过微型渗透泵输注首选 D3 激动剂普拉克索（PPX）四个半月，并在 PPX 开始后一个月；使用非病毒转染 NTS-polyplex 载体将 BDNF 基因转染到存活的黑质细胞中。在持续输注 PPX 的同时过表达 BDNF 基因，可恢复运动协调、平衡、正常步态和工作记忆。恢复还与纹状体投射神经元树突棘平均数量以及黑质和腹侧被盖区TH阳性神经元数量的恢复有关。这些积极的结果为进一步临床研究这种前景广阔的疗法铺平了道路。

{"title":"Transfection of the BDNF Gene in the Surviving Dopamine Neurons in Conjunction with Continuous Administration of Pramipexole Restores Normal Motor Behavior in a Bilateral Rat Model of Parkinson’s Disease","authors":"Alina Benítez-Castañeda, Verónica Anaya-Martínez, Armando de Jesús Espadas-Alvarez, Ana Luisa Gutierrez-Váldez, Luis Fernando Razgado-Hernández, Patricia Emmanuelle Reyna-Velazquez, Liz Quintero-Macias, Daniel Martínez-Fong, Benjamín Florán-Garduño, Jorge Aceves","doi":"10.1155/2024/3885451","DOIUrl":"https://doi.org/10.1155/2024/3885451","url":null,"abstract":"In Parkinson’s disease (PD), progressive degeneration of nigrostriatal innervation leads to atrophy and loss of dendritic spines of striatal medium spiny neurons (MSNs). The loss disrupts corticostriatal transmission, impairs motor behavior, and produces nonmotor symptoms. Nigral neurons express brain-derived neurotropic factor (BDNF) and dopamine D3 receptors, both protecting the dopamine neurons and the spines of MSNs. To restore motor and nonmotor symptoms to normality, we assessed a combined therapy in a bilateral rat Parkinson’s model, with only 30% of surviving neurons. The preferential D3 agonist pramipexole (PPX) was infused for four ½ months via mini-osmotic pumps and one month after PPX initiation; the BDNF-gene was transfected into the surviving nigral cells using the nonviral transfection NTS-polyplex vector. Overexpression of the BDNF-gene associated with continuous PPX infusion restored motor coordination, balance, normal gait, and working memory. Recovery was also related to the restoration of the average number of dendritic spines of the striatal projection neurons and the number of TH-positive neurons of the substantia nigra and ventral tegmental area. These positive results could pave the way for further clinical research into this promising therapy.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"193 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139924696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improvement by Medication Less than Expected in Parkinson’s Disease: Blinded Evaluation of Levodopa Response 帕金森病患者用药后的病情改善低于预期：左旋多巴反应的盲法评估

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-02-21 DOI: 10.1155/2024/2649578

Mette Niemann Johansen, Anna Handberg, Mohamed El Haddouchi, Josefine Grundtvig, Steen Rusborg Jensen, Lisette Salvesen, Annemette Løkkegaard

Background. The latest Movement Disorder Society (MDS) diagnostic criteria require a good and sustained response to medication to get a diagnosis of Parkinson’s disease, PD. Objective. The aim of this study was to evaluate levodopa response in a group of patients with probable PD, diagnosed by movement disorder specialists. Methods. An acute levodopa challenge test (LDCT) was performed after pausing the dopaminergic medication for 6 half-times. The motor part of the Unified Parkinson’s Disease Rating Scale was performed in the OFF-state and after LDCT (ON). A good effect was defined as >30% improvement. A video-protocol was used to secure standardized motor examination with blinded assessments of the UPDRS-III OFF and ON. An age-matched group of control subjects (CS) was included but did not go through LDCT. All participants were evaluated with Montreal Cognitive Assessment (MoCA) and Beck’s Depression Inventory (BDI). Results. In the statistical analysis, 37 patients were included. Twenty-one patients showed an improvement ≤30%, while 16 patients showed an improvement >30%. LDCT showed an overall mean improvement of 27.3% of motor UPDRS. In 43.2%, there was a discrepancy between the effect seen with the LDCT and the patients’ self-perceived medicine evaluation. Patients with PD had a significantly lower MoCA score and more depressive symptoms compared to CS. Conclusions. We showed an acute effect of levodopa using LDCT that was around 30% improvement. While it lends support to the use of this limit in the MDS diagnostic criteria, an acute effect of less than 30% should be considered acceptable in some patients. Our study highlights a discrepancy in the objective measure of medicine effect on motor symptoms and the patient’s subjective evaluation.

背景。最新的运动障碍协会（MDS）诊断标准要求，帕金森病（Parkinson's disease，PD）患者必须对药物治疗有良好且持续的反应，才能被诊断为帕金森病。研究目的本研究旨在评估由运动障碍专家确诊的一组疑似帕金森病患者对左旋多巴的反应。方法在暂停使用多巴胺能药物 6 次半后，进行急性左旋多巴挑战试验（LDCT）。统一帕金森病评分量表的运动部分在关机状态和 LDCT（开机）后进行。良好效果的定义是改善了 30%。采用视频协议确保了标准化的运动检查，并对UPDRS-III关机和开机状态进行了盲测。此外，还纳入了一组年龄匹配的对照受试者（CS），但没有进行LDCT检查。所有参与者都接受了蒙特利尔认知评估（MoCA）和贝克抑郁量表（BDI）的评估。结果统计分析共纳入 37 名患者。21名患者的病情改善率低于30%，16名患者的病情改善率为30%。LDCT 显示，运动型 UPDRS 的总体平均改善率为 27.3%。在43.2%的患者中，LDCT显示的效果与患者自我感觉的医学评估之间存在差异。与CS相比，PD患者的MoCA评分明显更低，抑郁症状更多。结论。我们利用 LDCT 显示了左旋多巴的急性疗效，改善幅度约为 30%。虽然这为在 MDS 诊断标准中使用这一限制提供了支持，但在某些患者中，低于 30% 的急性效果应被视为可以接受。我们的研究凸显了药物对运动症状影响的客观测量与患者主观评价之间的差异。

{"title":"Improvement by Medication Less than Expected in Parkinson’s Disease: Blinded Evaluation of Levodopa Response","authors":"Mette Niemann Johansen, Anna Handberg, Mohamed El Haddouchi, Josefine Grundtvig, Steen Rusborg Jensen, Lisette Salvesen, Annemette Løkkegaard","doi":"10.1155/2024/2649578","DOIUrl":"https://doi.org/10.1155/2024/2649578","url":null,"abstract":"Background. The latest Movement Disorder Society (MDS) diagnostic criteria require a good and sustained response to medication to get a diagnosis of Parkinson’s disease, PD. Objective. The aim of this study was to evaluate levodopa response in a group of patients with probable PD, diagnosed by movement disorder specialists. Methods. An acute levodopa challenge test (LDCT) was performed after pausing the dopaminergic medication for 6 half-times. The motor part of the Unified Parkinson’s Disease Rating Scale was performed in the OFF-state and after LDCT (ON). A good effect was defined as >30% improvement. A video-protocol was used to secure standardized motor examination with blinded assessments of the UPDRS-III OFF and ON. An age-matched group of control subjects (CS) was included but did not go through LDCT. All participants were evaluated with Montreal Cognitive Assessment (MoCA) and Beck’s Depression Inventory (BDI). Results. In the statistical analysis, 37 patients were included. Twenty-one patients showed an improvement ≤30%, while 16 patients showed an improvement >30%. LDCT showed an overall mean improvement of 27.3% of motor UPDRS. In 43.2%, there was a discrepancy between the effect seen with the LDCT and the patients’ self-perceived medicine evaluation. Patients with PD had a significantly lower MoCA score and more depressive symptoms compared to CS. Conclusions. We showed an acute effect of levodopa using LDCT that was around 30% improvement. While it lends support to the use of this limit in the MDS diagnostic criteria, an acute effect of less than 30% should be considered acceptable in some patients. Our study highlights a discrepancy in the objective measure of medicine effect on motor symptoms and the patient’s subjective evaluation.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"773 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139924747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preoperative Attention/Memory Problem Affects the Quality of Life of Parkinson's Disease Patients after Deep Brain Stimulation: A Cohort Study. 术前注意力/记忆力问题影响深部脑刺激术后帕金森病患者的生活质量：一项队列研究

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-02-07 eCollection Date: 2024-01-01 DOI: 10.1155/2024/3651705

Ying Gao, Jue Wang, Linbin Wang, Dianyou Li, Bomin Sun, Xian Qiu

Objectives: The aim of this study was to investigate the impact of nonmotor symptoms (NMS) on the quality of life (QoL) outcome after subthalamic nucleus deep brain stimulation (STN-DBS) at the 1-year follow-up.

Methods: Ninety-three patients diagnosed with Parkinson's disease (PD), who underwent subthalamic nucleus deep brain stimulation (STN-DBS) between April 2020 and August 2021, were included in this study. Demographic information was gathered through a self-designed questionnaire. The severity of both motor and non-motor symptoms, along with the quality of life (QoL), was assessed using the Unified Parkinson's Disease Rating Scale-III (UPDRS-III), Nonmotor Symptoms Scale (NMSS), and 8-item Parkinson's Disease Questionnaire (PDQ-8), respectively.

Results: Significant differences were observed in the UPDRS-III score, NMSS summary index (SI), and subscores of six domains (sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, urinary, and sexual function) between the baseline and the 6- and 12-month follow-ups. The correlation analysis revealed positive correlations between the preoperative NMSS SI and subscores of seven domains (cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastrointestinal, and urinary) and ΔPDQ-8. Moreover, the preoperative PDQ-8 SI (β = 0.869, P < 0.001) and the preoperative attention/memory subscore (β = -0.154, P = 0.026) were predictive of the postsurgery improvement in quality of life (QoL).

Conclusion: Deep brain stimulation (DBS) led to an improvement in the patients' nonmotor symptoms (NMS) at the 1-year follow-up, along with a correlation observed between NMS and the patients' quality of life (QoL). Notably, the severity of preoperative attention/memory problems emerged as the most significant predictor of NMS influencing the QoL outcome after STN-DBS at the 1-year follow-up.

研究目的本研究旨在探讨眼下核深部脑刺激术（STN-DBS）后1年随访期间非运动症状（NMS）对生活质量（QoL）结果的影响：本研究纳入了在2020年4月至2021年8月期间接受脑下核深部刺激术（STN-DBS）的93名帕金森病（PD）患者。研究人员通过自行设计的问卷收集了患者的人口统计学信息。分别使用统一帕金森病评分量表-III（UPDRS-III）、非运动症状量表（NMSS）和8项帕金森病问卷（PDQ-8）评估运动症状和非运动症状的严重程度以及生活质量（QoL）：在UPDRS-III评分、NMSS汇总指数（SI）以及六个领域（睡眠/疲劳、情绪/认知、感知问题/幻觉、注意力/记忆力、泌尿系统和性功能）的子评分方面，基线值与6个月和12个月随访值之间存在显著差异。相关性分析显示，术前 NMSS SI 与七个领域（心血管、睡眠/疲劳、情绪/认知、感知问题/幻觉、注意力/记忆力、胃肠道和泌尿系统）的子分数和 ΔPDQ-8 之间存在正相关。此外，术前 PDQ-8 SI（β = 0.869，P < 0.001）和术前注意力/记忆力子分数（β = -0.154，P = 0.026）对术后生活质量（QoL）的改善具有预测作用：结论：脑深部刺激术（DBS）使患者的非运动症状（NMS）在1年随访时得到改善，同时观察到NMS与患者生活质量（QoL）之间存在相关性。值得注意的是，术前注意力/记忆力问题的严重程度是影响 STN-DBS 术后 1 年生活质量的 NMS 最重要的预测因素。

{"title":"Preoperative Attention/Memory Problem Affects the Quality of Life of Parkinson's Disease Patients after Deep Brain Stimulation: A Cohort Study.","authors":"Ying Gao, Jue Wang, Linbin Wang, Dianyou Li, Bomin Sun, Xian Qiu","doi":"10.1155/2024/3651705","DOIUrl":"10.1155/2024/3651705","url":null,"abstract":"Objectives: The aim of this study was to investigate the impact of nonmotor symptoms (NMS) on the quality of life (QoL) outcome after subthalamic nucleus deep brain stimulation (STN-DBS) at the 1-year follow-up.Methods: Ninety-three patients diagnosed with Parkinson's disease (PD), who underwent subthalamic nucleus deep brain stimulation (STN-DBS) between April 2020 and August 2021, were included in this study. Demographic information was gathered through a self-designed questionnaire. The severity of both motor and non-motor symptoms, along with the quality of life (QoL), was assessed using the Unified Parkinson's Disease Rating Scale-III (UPDRS-III), Nonmotor Symptoms Scale (NMSS), and 8-item Parkinson's Disease Questionnaire (PDQ-8), respectively.Results: Significant differences were observed in the UPDRS-III score, NMSS summary index (SI), and subscores of six domains (sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, urinary, and sexual function) between the baseline and the 6- and 12-month follow-ups. The correlation analysis revealed positive correlations between the preoperative NMSS SI and subscores of seven domains (cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastrointestinal, and urinary) and ΔPDQ-8. Moreover, the preoperative PDQ-8 SI (β = 0.869, P < 0.001) and the preoperative attention/memory subscore (β = -0.154, P = 0.026) were predictive of the postsurgery improvement in quality of life (QoL).Conclusion: Deep brain stimulation (DBS) led to an improvement in the patients' nonmotor symptoms (NMS) at the 1-year follow-up, along with a correlation observed between NMS and the patients' quality of life (QoL). Notably, the severity of preoperative attention/memory problems emerged as the most significant predictor of NMS influencing the QoL outcome after STN-DBS at the 1-year follow-up.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2024 ","pages":"3651705"},"PeriodicalIF":3.2,"publicationDate":"2024-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10866634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139735839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease 关于拉沙吉林或普拉克索治疗早期帕金森病的疗效和安全性的系统回顾和荟萃分析

IF 3.2 4区医学 Q3 CLINICAL NEUROLOGY

Parkinson's Disease

Pub Date : 2024-01-16 DOI: 10.1155/2024/8448584

Pauli Seppänen, Markus M. Forsberg, Miia Tiihonen, Heikki Laitinen, Selena Beal, David C. Dorman

Background. Rasagiline or pramipexole monotherapy has been suggested for the management of early Parkinson’s disease (PD). The aim of this research was to systematically review the clinical efficacy and safety of rasagiline or pramipexole in early PD (defined as disease duration ≤5 years and Hoehn and Yahr stage of ≤3). Methods. Randomized controlled trials (RCTs) of rasagiline or pramipexole for early PD published up to September 2021 were retrieved. Outcomes of interest included changes in the Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II and III and the incidence of adverse events. Standardized mean difference (SMD), odds ratio (OR), and 95% confidence interval (CI) were calculated, and heterogeneity was measured with the I² test. Results. Nine rasagiline and eleven pramipexole RCTs were included. One post hoc analysis of one rasagiline study was included. Five studies for each drug were included in meta-analyses of the UPDRS scores. The rasagiline meta-analysis focused on patients receiving 1 mg/day. Rasagiline and pramipexole significantly improved UPDRS Part II and III scores when compared to placebo. Significant heterogeneity among the studies was present (I² > 70%). Neither rasagiline nor pramipexole increased the relative risk for any adverse events, serious adverse events, or adverse events leading to withdrawal when compared with placebo. Conclusion. Applying a Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach to summarize the evidence, we found moderate confidence in the body of evidence for the efficacy of rasagiline or pramipexole in early PD, suggesting further well-designed, multicenter comparative RCTs remain needed.

背景。有人建议使用拉沙吉林或普拉克索单药治疗早期帕金森病（PD）。本研究旨在系统回顾拉沙吉林或普拉克索治疗早期帕金森病（病程≤5年，Hoehn和Yahr分期≤3期）的临床疗效和安全性。研究方法检索截至2021年9月发表的拉沙吉林或普拉克索治疗早期帕金森病的随机对照试验（RCT）。研究结果包括统一帕金森病评分量表（UPDRS）第二部分和第三部分的变化以及不良事件的发生率。计算了标准化平均差 (SMD)、比值比 (OR) 和 95% 置信区间 (CI)，并通过 I2 检验测量了异质性。研究结果共纳入了九项拉沙吉林和十一项普拉克索的 RCT 研究。还纳入了对一项拉沙吉林研究的事后分析。每种药物均有五项研究被纳入UPDRS评分的荟萃分析。拉沙吉林的荟萃分析主要针对每天服用1毫克的患者。与安慰剂相比，拉沙吉林和普拉克索能明显改善UPDRS第二部分和第三部分的评分。研究之间存在明显的异质性（I2 >70%）。与安慰剂相比，拉沙吉林和普拉克索均未增加任何不良事件、严重不良事件或导致停药的不良事件的相对风险。结论应用建议、评估、发展和评价分级法（GRADE）对证据进行总结，我们发现拉沙吉林或普拉克索对早期帕金森病疗效的证据可信度为中等，这表明仍需进一步开展设计良好的多中心对比性RCT研究。

{"title":"A Systematic Review and Meta-Analysis of the Efficacy and Safety of Rasagiline or Pramipexole in the Treatment of Early Parkinson’s Disease","authors":"Pauli Seppänen, Markus M. Forsberg, Miia Tiihonen, Heikki Laitinen, Selena Beal, David C. Dorman","doi":"10.1155/2024/8448584","DOIUrl":"https://doi.org/10.1155/2024/8448584","url":null,"abstract":"Background. Rasagiline or pramipexole monotherapy has been suggested for the management of early Parkinson’s disease (PD). The aim of this research was to systematically review the clinical efficacy and safety of rasagiline or pramipexole in early PD (defined as disease duration ≤5 years and Hoehn and Yahr stage of ≤3). Methods. Randomized controlled trials (RCTs) of rasagiline or pramipexole for early PD published up to September 2021 were retrieved. Outcomes of interest included changes in the Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II and III and the incidence of adverse events. Standardized mean difference (SMD), odds ratio (OR), and 95% confidence interval (CI) were calculated, and heterogeneity was measured with the I2 test. Results. Nine rasagiline and eleven pramipexole RCTs were included. One post hoc analysis of one rasagiline study was included. Five studies for each drug were included in meta-analyses of the UPDRS scores. The rasagiline meta-analysis focused on patients receiving 1 mg/day. Rasagiline and pramipexole significantly improved UPDRS Part II and III scores when compared to placebo. Significant heterogeneity among the studies was present (I2 > 70%). Neither rasagiline nor pramipexole increased the relative risk for any adverse events, serious adverse events, or adverse events leading to withdrawal when compared with placebo. Conclusion. Applying a Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach to summarize the evidence, we found moderate confidence in the body of evidence for the efficacy of rasagiline or pramipexole in early PD, suggesting further well-designed, multicenter comparative RCTs remain needed.","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"7 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139477082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0